Shortage of Abatacept (Orencia®) Resolved – update
Update: August 28, 2024.
Bristol Myers Squibb (BMS), the manufacturer of Orencia (abatacept), has announced that the shortage of subcutaneous abatacept will be resolved as of the 30 August 2024.
Starting from 30 August 2024:
- The TGA medicine shortage notification for abatacept 125 mg single dose syringe will no longer be in place.
- The abatacept 125 mg single-dose syringe, BMS, China Stock approved under Section 19A will no longer be available.
- Normal ordering processes for both abatacept pre-filled syringe and ClickJect autoinjector can resume via the DHL online portal.
- Patients may switch back to, or new patients may be initiated on, any of the abatacept presentations as deemed appropriate by the treating physician.
Patients should consult with their healthcare providers for further information.
Discover more...
-
Arthritis Australia’s first interactive Parliamentary Summit on Better Care for Arthritis and Musculoskeletal Conditions
Arthritis Australia’s first interactive Parliamentary Summit on Better Care for Arthritis and Musculoskeletal Conditions on 22 August was attended by over 90 consumers, clinicians, researchers,...
-
Arthritis and musculoskeletal conditions affect 7 million Australians
Arthritis and musculoskeletal conditions affect almost 1 in 3 Australians 7 million voices | 7 million stories One in three, which is more than 7...
-
World Arthritis Day | 2024
World Arthritis Day 2024: Empowering Through Information October 12th marks World Arthritis Day, a global initiative to recognise the challenges faced by millions living with...
Sign up to Arthritis Insights
Regular updates, news and research findings delivered to your inbox:
